The U. S. pharmaceutical supply chain's reliance on Chinese inputs poses a significant risk to public health. As the Trump administration discusses various international issues during the summit with Xi Jinping, the importance of addressing this vulnerability should be prioritized.
• The dependence on China is exemplified by heparin, a vital blood thinner used in numerous medical procedures in the U. S.
• Heparin’s raw material, porcine intestinal mucosa, is sourced from small workshops in China's Shandong Province, with about 70% of U. S. heparin coming this way.
• Significant U. S. production of heparin is owned by Chinese companies, and no independent American producer exists.
• Historical incidents of contaminated heparin from China resulted in 149 American deaths and highlighted the risks in the supply chain, with no accountability for Chinese officials.
• Despite the past issues, U. S. pharmaceutical companies continue to prioritize cost over security, treating dependence on Chinese sources as a given.
• Recent supply challenges, including Pfizer's heparin shortage and Mylan’s market exit, indicate a diminishing number of suppliers, increasing reliance on a supply chain controlled by China.
• Concerns about potential “weaponization” of pharmaceutical supplies by China are valid, as the country's government has been reinforcing its dominance over supply chains, according to the Rhodium Group's analysis.
• Beijing's 15th Five-Year Plan focuses on biomanufacturing and aims to enhance its control over critical supply chains.
The risks associated with U. S. dependency on Chinese pharmaceutical inputs need urgent attention. As the Trump administration engages in global discussions, elevating the importance of securing and diversifying these supply chains is crucial to protect American health interests.
https://nationalinterest.org/feature/chinas-pharmaceutical-weapon
No comments:
Post a Comment